Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Eytan Stein on Novel Combinations in AML

Eytan M. Stein, MD
Published: Tuesday, Nov 29, 2016



Eytan M. Stein, MD, internist, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the potential combinations that could be explored with novel agents in the treatment of patients with acute myeloid leukemia (AML).
 
With several new agents in the pipeline for AML, Stein sees endless possibilities for combination regimens. One novel agent is midostaurin, which has demonstrated a 7% overall survival benefit at approximately 5 years when combined with induction chemotherapy for patients with FLT3-positive AML.
 
Some clinical studies have examined combinations involving the BCL-2 inhibitor venetoclax (Venclexta), or the novel antibody-drug conjugate SGN-CD33A, paired with hypomethylating agents.
 
Overall, Stein sees this as a very exciting time in AML. There have not been any new drug approvals for this disease in the past several years, so many experts would agree that the field is now long overdue for one in the coming years.


Eytan M. Stein, MD, internist, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the potential combinations that could be explored with novel agents in the treatment of patients with acute myeloid leukemia (AML).
 
With several new agents in the pipeline for AML, Stein sees endless possibilities for combination regimens. One novel agent is midostaurin, which has demonstrated a 7% overall survival benefit at approximately 5 years when combined with induction chemotherapy for patients with FLT3-positive AML.
 
Some clinical studies have examined combinations involving the BCL-2 inhibitor venetoclax (Venclexta), or the novel antibody-drug conjugate SGN-CD33A, paired with hypomethylating agents.
 
Overall, Stein sees this as a very exciting time in AML. There have not been any new drug approvals for this disease in the past several years, so many experts would agree that the field is now long overdue for one in the coming years.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x